DelveInsight’s “Venous Leg Ulcers Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Venous Leg Ulcers market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Venous Leg Ulcers drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Venous Leg Ulcers treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Venous Leg Ulcers: An Overview
Venous ulcers are leg ulcers caused by problems with blood flow (circulation) in the leg veins. Usually, when a cut or scrape occurs, the body’s healing process starts working to close the wound. In time, the wound heals, but ulcers may not heal without proper treatment.
Venous ulcers typically occur because of damage to the valves inside the leg veins. These valves control the blood pressure inside the veins, and they allow it to drop when a person walks. If the blood pressure inside the leg veins does not fall as the person is walking, the condition is called sustained venous hypertension, which increases the blood pressure and causes ulcers to form on the ankles.
The classification and staging of chronic venous insufficiency (clinical severity) can be measured by a scoring system called clinical manifestations, etiological factors, anatomical distribution, and pathophysiological Conditions.
Treatment options for venous ulcers include conservative management, mechanical modalities, medications, advanced wound therapy, and surgical options. Although the main goal of treatment is ulcer healing, secondary goals include reducing edema and preventing recurrence.
Venous Leg Ulcers Market Key Facts
As per Millan et al. (2019), in the United States, 10–35% of adults have chronic venous insufficiency (CVI), whose chronic manifestation causes venous ulcers. It is responsible for about 70% of chronic ulcers of the lower limbs.
As per the National Health Service (NHS, n.d.), venous leg ulcers are estimated to affect around 1 in 500 people in the UK, although they become much more common with age.
Wei et al. (2015), reported a higher prevalence of venous leg ulcers (VLUs) in women, although this disparity decreases with age, and in fact, various cross-sectional studies suggest the male gender carried a higher risk of developing VLU.
As per Wei et al. (2015), more Prevalent Cases of venous leg ulcers (VLU) are seen in women, although this disparity decreases with age, and in fact, a more recent cross-sectional study suggests male gender carries a higher risk of developing VLU. Nevertheless, the overall economic and social burden worldwide is huge.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Venous Leg Ulcers pipeline therapies. It also thoroughly assesses the Venous Leg Ulcers market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Venous Leg Ulcers drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Venous Leg Ulcers Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Venous Leg Ulcers epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Venous Leg Ulcers epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Venous Leg Ulcers Epidemiology, Segmented as –
Total Prevalent Cases of Venous Leg Ulcer in the 7MM [2019–2032]
Gender-specific Prevalent Cases of Venous Leg Ulcer in the 7MM [2019–2032]
Diagnosed and Treatable Cases of Venous Leg Ulcer in the 7MM [2019–2032]
Venous Leg Ulcers Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Venous Leg Ulcers market or expected to be launched during the study period. The analysis covers the Venous Leg Ulcers market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Venous Leg Ulcers drugs based on their sale and market share.
The report also covers the Venous Leg Ulcers pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Venous Leg Ulcers companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Venous Leg Ulcers Market Will Evolve and Grow by 2032 @
Venous Leg Ulcers Therapeutics Analysis
The treatment of chronic venous ulcers is a therapeutic challenge, and a comprehensive diagnostic evaluation is therefore essential at the start of treatment. For venous ulcers, apart from conservative treatment, reducing venous hypertension is critical, with compression therapy occupying an important place in achieving this. Patients with nonhealing venous ulcers who have had compression therapy and have no deep vein incompetence are recommended for superficial venous surgery, foam sclerotherapy, or ligation of the affected vein as an important aspect of the overall treatment plan.
Sometimes minor surgery (wound debridement) or vein ablation (a nonsurgical technique that closes a vein) is used to remove any nonliving tissue that keeps a wound from healing properly.
Several major companies are developing therapies for Venous Leg Ulcers. Currently, Energenesis Biomedical is leading the therapeutics market with its drug candidates in the most advanced stage of clinical development. allo-APZ2-CVU, EscharEx, and other emerging therapies are giving positive topline results in their clinical trials. These emerging therapies are in the mid-phase of their clinical trials and are awaiting a launch – expected to make the pipeline robust.
Venous Leg Ulcers Companies Actively Working in the Therapeutics Market Include
Promore Pharma AB
And Many Others
Emerging and Marketed Venous Leg Ulcers Products Covered in the Report Include:
ENERGI-F703: Energenesis Biomedical
allo-APZ2-CVU: RHEACELL GmbH & Co. KG
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Venous Leg Ulcers Competitive Intelligence Analysis
4. Venous Leg Ulcers Market Overview at a Glance
5. Venous Leg Ulcers Disease Background and Overview
6. Venous Leg Ulcers Patient Journey
7. Venous Leg Ulcers Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Venous Leg Ulcers Treatment Algorithm, Current Treatment, and Medical Practices
9. Venous Leg Ulcers Unmet Needs
10. Key Endpoints of Venous Leg Ulcers Treatment
11. Venous Leg Ulcers Marketed Therapies
12. Venous Leg Ulcers Emerging Drugs and Latest Therapeutic Advances
13. Venous Leg Ulcers Seven Major Market Analysis
14. Attribute Analysis
15. Venous Leg Ulcers Market Outlook (In US, EU5, and Japan)
16. Venous Leg Ulcers Companies Active in the Market
17. Venous Leg Ulcers Access and Reimbursement Overview
18. KOL Views on the Venous Leg Ulcers Market
19. Venous Leg Ulcers Market Drivers
20. Venous Leg Ulcers Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Cryptococcosis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Cryptococcosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Cryptococcosis market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States